Carna Health and Kazakhstan sign MOU on early detection of CKM disease

Carna Health, an AI-enabled digital health company focused on chronic disease prevention, has signed a Memorandum of Understanding (MOU) with the Ministry of Health of the Republic of Kazakhstan to support earlier detection and prevention of cardio-kidney-metabolic (CKM) disease.

Under the agreement, Carna Health and the ministry will evaluate pilot initiatives using digital health technologies, evidence-based clinical pathways and population health management to strengthen preventive care across Kazakhstan.

The partnership forms part of the country’s broader commitment to advancing preventive healthcare.

Dr Salvatore Viscomi, co-founder and chief executive officer of Carna Health, said the company looked forward to exploring how AI-enabled early detection and intervention can improve health outcomes.

Dr Akmaral Alnazarova, Minister of Health of the Republic of Kazakhstan, said the agreement reflected a shared vision of improving early detection and supporting better patient outcomes.

Carna Health on a mission to prevent chronic disease worldwide through data and partnerships

The agreement is the latest step in Carna Health’s international expansion, as the company works with governments, healthcare systems, clinicians and strategic partners to address CKM disease, a category that includes cardiovascular disease, chronic kidney disease, diabetes, hypertension, obesity and dyslipidaemia.

The company said the condition is contributing to rising healthcare costs, growing demand for care and reduced workforce productivity in countries worldwide, including Kazakhstan.

Marcia Favale, an advisory board member at Carna Health, described Kazakhstan as an ideal partner for Carna Health as it expands globally.

Carna Health’s approach is aimed at identifying at-risk individuals earlier, allowing healthcare providers to intervene before serious complications develop.

The Kazakhstan agreement follows a broader global expansion of Carna Health’s AI-driven chronic kidney disease (CKD) screening programmes, announced earlier this year around World Kidney Day, with new initiatives launched across Latin America, Africa and Asia.

Southeast Asia entered the rollout through the Philippines, targeting more than 300,000 individuals across Manila, Quezon City and Cagayan province, with an Indonesia pilot targeting 10,000 people to follow later in 2026.